芪苈强心减轻阿霉素诱导的小鼠心脏损伤

doi:10.12066/j.issn.1007-2861.2015

Abstract

Abstract:

To investigate the therapeutic effects of Qiliqiangxin (QLQX) in doxorubicin (DOX)-induced cardiac dysfunction in vivo. Male mice aged 7~9 weeks were randomly divided into several groups. DOX (4 mg/kg) was injected to induce cardiotoxicity via intraperitoneal administration weekly, and QLQX was given by gavage every day for 4 weeks at a dose of 0.5 g/(kg$\cdot$d). After 4 weeks, echocardiography was performed to detect the cardiac function and it was showed that cardiac function could be significantly improved in mice treated with QLQX versus the saline. These findings indicated that QLQX could function as an intervening treatment for the patients who were treated with DOX.

Key words: Qiliqiangxin (QLQX), doxorubicin (DOX), cardiotoxicity, mitochondria

CLC Number:

R541

WU Xiaodong, JIANG Huimin, YAO Wenming, GAO Rongrong, LI Xinli. Qiliqiangxin attenuates doxorubicin induced cardiac dysfunction in mice[J]. Journal of Shanghai University（Natural Science Edition）, 2018, 24(2): 192-197.

Figures/Tables 5

References 15

[1]	Carvalho F S, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy[J]. Medicinal Research Reviews, 2014,34:106-135. pmid: 23494977
[2]	Arif I S, Hooper C L, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARgamma-ligands and by exploiting circadian rhythms[J]. British Journal of Pharmacology, 2013,169:1178-1188. doi: 10.1111/bph.12202 pmid: 23578093
[3]	Zhao L, Qi Y, Xu L, et al. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting nrf2 and sirt2[J]. Redox Biology, 2018,15:284-296. doi: 10.1016/j.redox.2017.12.013 pmid: 29304479
[4]	Li S, Wang W, Niu T, et al. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction[J]. Oxid Med Cell Longev, 2014,2014:748524. doi: 10.1155/2014/748524 pmid: 24895528
[5]	Steinherz L J, Steinherz P G, Tan C, et al. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients[J]. Pediatric Blood & Cancer, 1995,24(6):352.
[6]	Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity[J]. Oxid Med Cell Longev, 2017(16):1521020.
[7]	Fernandez-Chas M, Curtis M J, Niederer S A. Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model[J]. British Journal of Pharmacology, 2017, DOI: 10.1111/bph.14104. doi: 10.1111/bph.15186 pmid: 32608017
[8]	Li M S V, De Santis M C, Cimino J, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, DOI: 10.1161/CIRCULATIONAHA.117.030352. doi: 10.1161/CIRCULATIONAHA.119.045526 pmid: 32654539
[9]	Yuan Y P, Ma Z G, Zhang X, et al. Ctrp3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of sirt1[J]. Journal of Molecular and Cellular Cardiology, 2018,114:38-47. doi: 10.1016/j.yjmcc.2017.10.008 pmid: 29061338
[10]	Tony H, Yu K, Qiu T Z. MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction[J]. Oxid Med Cell Longev, 2015(17):597032.
[11]	Tao L, Shen S, Fu S, et al. Traditional Chinese medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice[J]. Scientific Reports, 2015, DOI: 10.1038/srep08374. doi: 10.1038/s41598-020-68334-2 pmid: 32665664
[12]	Lin S, Wu X, Tao L, et al. The metabolic effects of traditional Chinese medication Qiliqiangxin on h9c2 cardiomyocytes[J]. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 2015,37:2246-2256.
[13]	Zhang J, Wei C, Wang H, et al. Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evidence-Based Complementary and Alternative Medicine, 2013,2013:378298. doi: 10.1155/2013/378298 pmid: 24078824
[14]	Yarana C, Carroll D, Chen J, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury[J]. Clinical Cancer Research, 2017, DOI: 10.1158/1078-0432.CCR-17-2046. doi: 10.1158/1078-0432.CCR-20-1828 pmid: 32611629
[15]	Khiati S, Dalla Rosa I, Sourbier C, et al. Mitochondrial topoisomerase 1 (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity[J]. Clinical Cancer Research, 2014,20:4873-4881. doi: 10.1158/1078-0432.CCR-13-3373 pmid: 24714774

Qiliqiangxin attenuates doxorubicin induced cardiac dysfunction in mice

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 15

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	HOU Wenlin, PAN Wen, FU Siyi, SONG Meiyi, WANG Fei. Dysfunction of mitochondrial in mice with non-alcoholic steatohepatitis [J]. Journal of Shanghai University（Natural Science Edition）, 2019, 25(1): 1-9.
[2]	LI Yuyu, JIN Youxin, XU Zhongjuan, ZHANG Shumang, SUO Guangli. Effects of ABL silencing combined with TRAIL and DOX on apoptosis of colorectal cancer HT29 cells [J]. Journal of Shanghai University（Natural Science Edition）, 2018, 24(1): 134-141.